From: Characteristics of clinical trials related to hip fractures and factors associated with completion
Characteristics | Rates | Simple logistic regression | Multiple logistic regression | ||
---|---|---|---|---|---|
OR (95% CI) | P | OR (95% CI) | P | ||
Outcome measures including mortality | |||||
Yes | 6.25% (5/80) | 0.64 (0.24–1.67) | 0.36 | 1.25 (0.35–4.49) | 0.73 |
No | 9.49% (37/390) | ||||
Gender | |||||
Male | 25.00% (1/4) | 2.08 (0.35–12.28) | 0.42 | 3.07 (0.42–22.46) | 0.27 |
Female | 6.67% (1/15) | ||||
Both | 8.87% (40/451) | ||||
Age including children | |||||
Yes | 5.00% (2/40) | 0.51 (0.12–2.21) | 0.37 | 1.30 (0.22–7.63) | 0.77 |
No | 9.30% (40/430) | ||||
Age including older adults | |||||
Yes | 8.89% (41/461) | 0.78 (0.10–6.40) | 0.82 | 0.96 (0.08–11.59) | 0.97 |
No | 11.11% (1/9) | ||||
Phases | |||||
Not applicable | 5.71% (18/315) | 1.30 (1.08–1.55) | < 0.01 | 1.05 (0.77–1.44) | 0.74 |
Phase 1 | 0.00% (0/4) | ||||
Phase 2 | 25.93% (7/27) | ||||
Phase 3 | 16.33% (8/49) | ||||
Phase 4 | 12.00% (9/75) | ||||
Enrollment | |||||
≤ 50 | 12.90% (16/124) | 0.89 (0.69–1.15) | 0.39 | 0.71 (0.51–0.99) | 0.04 |
> 50 and ≤ 100 | 7.14% (9/126) | ||||
> 100 and ≤ 200 | 6.60% (7/106) | ||||
> 200 and ≤ 400 | 7.35% (5/68) | ||||
> 400 | 10.87% (5/46) | ||||
Funded by the NIH | |||||
Yes | 33.33% (6/18) | 5.78 (2.05–16.31) | < 0.01 | 7.55 (1.48–38.56) | 0.02 |
No | 7.96% (36/452) | ||||
Funded by industry | |||||
Yes | 23.61% (17/72) | 4.61 (2.34–9.09) | < 0.01 | 6.32 (2.43–16.44) | < 0.01 |
No | 6.28% (25/398) | ||||
Allocation | |||||
Not applicable | 1.92% (1/52) | 1.53 (0.82–2.85 | 0.18 | 1.28 (0.42–3.92) | 0.66 |
Non-randomized | 13.89% (5/36) | ||||
Randomized | 9.42% (36/382) | ||||
Intervention model | |||||
Single | 3.85% (3/78) | 1.30 (0.89–1.91) | 0.18 | 1.54 (0.76–3.10) | 0.23 |
Sequential | 0.00% (0/3) | ||||
Parallel | 10.19% (37/363) | ||||
Factorial | 11.11% (1/9) | ||||
Crossover | 5.88% (1/17) | ||||
Masking | |||||
None | 9.68% (18/186) | 1.24 (0.99–1.56) | 0.06 | 0.83 (0.59–1.17) | 0.28 |
Single | 4.80% (6/125) | ||||
Double | 3.61% (3/83) | ||||
Triple | 21.43% (6/28) | ||||
Quadruple | 18.75% (9/48) | ||||
Primary purpose | |||||
Diagnostic | |||||
Yes | 6.25% (1/16) | 0.67 (0.09–5.21) | 0.70 | 0.41 (0.01–24.96) | 0.67 |
No | 9.03% (41/454) | ||||
Health service research | |||||
Yes | 0.00% (0/13) | 0.01 (0.00–99.99) | 0.98 | 0.01 (0.00–99.99) | 0.98 |
No | 9.19% (42/457) | ||||
Prevention | |||||
Yes | 13.51% (10/74) | 1.78 (0.83–3.79) | 0.14 | 1.20 (0.10–14.56) | 0.89 |
No | 8.08% (32/396) | ||||
Supportive care | |||||
Yes | 0.00% (0/27) | 0.01 (0.00–99.99) | 0.98 | 0.01 (0.00–99.99) | 0.98 |
No | 9.48% (42/443) | ||||
Treatment | |||||
Yes | 9.38% (30/320) | 1.19 (0.59–2.39) | 0.63 | 0.70 (0.07–7.40) | 0.77 |
No | 8.00% (12/150) | ||||
Interventions | |||||
Behavioral | |||||
Yes | 2.94% (1/34) | 0.29 (0.04–2.19) | 0.23 | 0.18 (0.01–2.52) | 0.20 |
No | 9.40% (41/436) | ||||
Drug/biological | |||||
Yes | 17.61% (25/142) | 3.91 (2.04–7.50) | < 0.01 | 4.47 (1.19–16.83) | 0.03 |
No | 5.18% (17/328) | ||||
Device | |||||
Yes | 12.17% (14/115) | 1.62 (0.82–3.19) | 0.16 | 2.53 (0.77–8.29) | 0.12 |
No | 7.89% (28/355) | ||||
Procedure | |||||
Yes | 4.55% (6/132) | 0.40 (0.16–0.97) | 0.04 | 0.99 (0.34–2.90) | 0.99 |
No | 10.65% (36/338) | ||||
Location in China | |||||
Yes | 4.55% (2/44) | 0.46 (0.11–1.97) | 0.30 | 1.91 (0.26–13.86) | 0.52 |
No | 9.39% (40/426) | ||||
Location in the United States | |||||
Yes | 29.00% (29/100) | 11.22 (5.56–22.63) | < 0.01 | 9.43 (2.41–36.95) | < 0.01 |
No | 3.51% (13/370) | ||||
Location in Europe | |||||
Yes | 3.06% (6/196) | 0.21 (0.09–0.51) | < 0.01 | 0.89 (0.20–4.00) | 0.88 |
No | 13.14% (36/274) | ||||
Location in Canada | |||||
Yes | 6.45% (2/31) | 0.69 (0.16–2.99) | 0.62 | 1.96 (0.25–15.67) | 0.53 |
No | 9.11% (40/439) |